title: Association of ERCC2/XPD polymorphisms and interaction with tobacco smoking in lung cancer susceptibility: a systemic review and meta-analysis.
abstract: The association of the two ERCC polymorphisms, Asp312Asn and Lys751Gln, with lung cancer risk remains controversial and inconclusive. To better evaluate the potential role of the two polymorphisms and interaction with tobacco smoking in lung cancer susceptibility presented in diverse populations, we have conducted a meta-analysis based on 26 studies from 24 publications which included analyses of Asp312Asn (7121 cases, 8962 controls) and Lys751Gln (8396 cases, 10510 controls) polymorphisms. Overall, significantly elevated lung cancer risk was associated with ERCC2 312Asn allele(homozygous model: OR=1.20[1.05-1.36], P=0.006; recessive model: OR=1.20[1.06-1.35], P=0.004) and 751Gln allele(homozygous model: OR=1.31[1.17-1.46], P<0.00001; heterozygous model: OR=1.11[1.04-1.19], P=0.003; recessive model: OR=1.23[1.11-1.37], P<0.0001; dominant model: OR=1.15[1.08-1.23], P<0.0001). In ethnic subgroup analyses, significantly increased risk was associated with ERCC2 312Asn allele for both Caucasians and Asians, and 751Gln allele for both Caucasians and Latino-Americans. When stratified by smoking status, significantly elevated risk of both polymorphisms for never-smokers was detected (dominant model, OR=1.46[1.09-1.95] and 1.57[1.19-2.08], P=0.01 and 0.002, respectively). In conclusion, this meta-analysis suggests that the two ERCC2 polymorphisms may contribute to lung cancer susceptibility serving as low-penetrance risk factors. Extremely large-scale evidence would be necessary to confirm the effects on ethnically specific populations and gene-environment interactions.
authors: Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021, People's Republic of China.
authors: Zhen
authors: Z
authors: Feng
authors: Yang
authors: Y
authors: Ni
authors: Wei
authors: W
authors: Dong
authors: Hongchang
authors: H
authors: Shen
authors: Jiajun
authors: J
authors: Du
references: Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30
references: 12496039
references: Cancer Res. 2001 Feb 15;61(4):1354-7
references: 11245433
references: Am J Hum Genet. 2009 Nov;85(5):679-91
references: 19836008
references: J Natl Cancer Inst. 2009 Jan 7;101(1):24-36
references: 19116388
references: J Clin Oncol. 2007 Feb 10;25(5):561-70
references: 17290066
references: Cancer Lett. 2003 Mar 10;191(2):171-8
references: 12618330
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: Clin Lung Cancer. 2007 May;8(6):369-75
references: 17562237
references: Cancer Genet Cytogenet. 2006 Aug;169(1):27-32
references: 16875933
references: Cancer Genet Cytogenet. 2007 May;175(1):47-51
references: 17498557
references: DNA Repair (Amst). 2007 Sep 1;6(9):1264-70
references: 17403617
references: BMC Cancer. 2007 Aug 16;7:162
references: 17705814
references: Carcinogenesis. 2002 Apr;23(4):599-603
references: 11960912
references: Mutat Res. 2007 Jul 28;631(2):101-10
references: 17531525
references: Carcinogenesis. 2002 Aug;23(8):1321-5
references: 12151350
references: Contemp Clin Trials. 2007 Feb;28(2):105-14
references: 16807131
references: Biometrics. 1994 Dec;50(4):1088-101
references: 7786990
references: Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):674-7
references: 12869411
references: J Thorac Oncol. 2010 Sep;5(9):1337-45
references: 20651612
references: Int J Med Sci. 2007 Feb 01;4(2):59-71
references: 17299578
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):507-17
references: 18349268
references: Am J Epidemiol. 2006 Aug 15;164(4):297-302
references: 16707649
references: Int J Cancer. 2005 Sep 20;116(5):768-73
references: 15849729
references: BMC Med Res Methodol. 2002 Aug 09;2:10
references: 12171604
references: Genetics. 2008 Nov;180(3):1609-16
references: 18791257
references: Cancer Res. 2002 Mar 1;62(5):1377-81
references: 11888908
references: Environ Health Perspect. 2003 Nov;111(15):1843-50
references: 14630517
references: Breast Cancer Res Treat. 2010 Nov;124(2):531-41
references: 20379847
references: Pharmacogenet Genomics. 2007 Nov;17(11):897-905
references: 18075460
references: Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):911-2
references: 11489761
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Carcinogenesis. 2001 Apr;22(4):593-7
references: 11285194
references: Int J Cancer. 2008 Nov 1;123(9):2095-104
references: 18709642
references: Lung Cancer. 2002 Apr;36(1):15-6
references: 11891028
references: Carcinogenesis. 2006 Mar;27(3):560-7
references: 16195237
references: Carcinogenesis. 2004 Dec;25(12):2433-41
references: 15333465
references: Am J Epidemiol. 2005 Jan 1;161(1):1-14
references: 15615908
references: Carcinogenesis. 2002 Feb;23(2):295-9
references: 11872635
references: Environ Mol Mutagen. 2004;44(1):74-82
references: 15199549
references: Carcinogenesis. 2000 Apr;21(4):551-5
references: 10753184
references: J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210
references: 10413421
references: J Exp Clin Cancer Res. 2009 Dec 14;28:153
references: 20003391
references: Lancet Oncol. 2010 Apr;11(4):321-30
references: 20304703
references: Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1336-40
references: 16835333
references: Lung Cancer. 2002 Nov;38(2):123-9
references: 12399122
references: Mutat Res. 2004 Feb 26;546(1-2):65-74
references: 14757194
references: Lung Cancer. 2008 Feb;59(2):171-9
references: 17913280
references: Med Oncol. 2011 Sep;28(3):655-60
references: 20354818
references: Carcinogenesis. 2008 Aug;29(8):1560-6
references: 18635523
references: Carcinogenesis. 2006 May;27(5):997-1007
references: 16308313
references: J Cancer Res Clin Oncol. 2008 Jun;134(6):645-52
references: 17952468
references: Int J Cancer. 2003 Jul 10;105(5):669-73
references: 12740916
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120